

SEP 01 2005

## SIDLEY AUSTIN BROWN &amp; WOOD LLP

1501 K STREET, NW - WASHINGTON, D.C. 20005 - TEL. (202) 736-8000 - FAX (202) 736-8711

## FAX TRANSMISSION

Total ~~13~~ 1 pages, including cover sheet

To: Commissioner for Patents  
U.S. Patent and Trademark Office Fax no.: (571) 273-8300

From: David L. Fitzgerald  
Tel. (202) 736-8000

Date: 1 September 2005

## Re:

Serial No.: 09/436,347	Group Art Unit: 1643
Confirmation No.: 6491	Examiner: A.M. Harris
Filed: 9 November 1999	
Applicant: Christine A. WHITE et al.	
For: Treatment of Hematologic Malignancies Associated with Circulating Tumor Cells Using Chimeric Anti-CD20 Antibody	

## CERTIFICATE OF TRANSMISSION UNDER 37 C.F.R. § 1.8

I CERTIFY THAT THE FOLLOWING DOCUMENTS ARE BEING TRANSMITTED TO THE USPTO AT FAX NUMBER (703) 872-9306 ON THE DATE SHOWN:

- Transmittal
- Power of Attorney by Assignee and Change of Correspondence Address

  
SIGNATUREYVONNE T. REYES  
PRINTED NAMESept. 1, 2005  
DATE

THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE INDIVIDUAL OR ENTITY TO WHICH IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL AND EXEMPT FROM DISCLOSURE UNDER APPLICABLE LAW. IF THE READER OF THIS MESSAGE IS NOT THE INTENDED RECIPIENT OR THE EMPLOYEE OR AGENT RESPONSIBLE FOR DELIVERING THE MESSAGE TO THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT ANY DISSEMINATION, DISTRIBUTION OR COPYING OF THIS COMMUNICATION IS STRICTLY PROHIBITED. IF YOU HAVE RECEIVED THIS COMMUNICATION IN ERROR, NOTIFY US IMMEDIATELY BY TELEPHONE, AND RETURN THE ORIGINAL MESSAGE TO US AT THE ABOVE ADDRESS VIA THE US POSTAL SERVICE. THANK YOU.

SEP 01 2005

Serial no. 09/436,347

Attorney Docket no. 27693-01201

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Serial No.:	09/436,347	Group Art Unit:	1643
Confirmation No.:	6491	Examiner:	A.M. Harris
Filed:	9 November 1999		
Inventor:	Christine A. WHITE <i>et al.</i>		
For:	Treatment of Hematologic Malignancies Associated with Circulating Tumor Cells Using Chimeric Anti-CD20 Antibody		

Mail Stop AF  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

TRANSMITTAL

Transmitted for filing in the captioned application is a combined Power of Attorney by the assignee and Change of Correspondence Address. We believe that no fee is due in connection with this submission.

Should any fee under 37 C.F.R. §§ 1.16 or 1.17 be required to render this or any other paper filed during the pendency of this application timely or proper, the Director is requested to charge the appropriate amount to our Deposit Account No. 18-1260.

Respectfully submitted,



David L. Fitzgerald, Reg. No. 47,347  
Attorney for Biogen Idec Inc.

Date: 01 Sept 05

SIDLEY AUSTIN BROWN & WOOD LLP  
1501 K Street, N.W.  
Washington, DC 20005  
tel. (202) 736-8818  
fax (202) 736-8711

Aug 24 00 04:00

Biogen Inc.

0004010100

p.2

Serial no. 09/436,347

Attorney Docket no. 27693-01201

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Serial No.:	09/436,347	Group Art Unit:	1643
Confirmation No.:	6491	Examiner:	A.M. Harris
Filed:	9 November 1999		
Inventor:	Christine A. WHITE <i>et al.</i>		
For:	Treatment of Hematologic Malignancies Associated with Circulating Tumor Cells Using Chimeric Anti-CD20 Antibody		

Mail Stop AF  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

POWER OF ATTORNEY BY ASSIGNEE AND CHANGE OF CORRESPONDENCE ADDRESS

The assignee of the entire right, title, and interest in U.S. patent application serial no. 09/436,347, Biogen Idec Inc., hereby revokes all previous powers of attorney in the above-identified application and appoints the practitioners associated with

**CUSTOMER NUMBER 47553**

as its attorneys and agents to prosecute the captioned patent application, and to transact all business in the U.S. Patent and Trademark Office connected therewith.


Direct all correspondence regarding this application to the address associated with **CUSTOMER NUMBER 47553.**

Please note the new attorney docket number for this application, 27693-01201.

Pursuant to 37 C.F.R. § 3.73(b), the undersigned states that Biogen Idec Inc. is the assignee of the entire right, title, and interest in the captioned application by virtue of an assignment by the inventors to IDEC Pharmaceuticals Corp. recorded at Reel 010464/ Frame 0829. IDEC Pharmaceuticals Corp. now conducts business as Biogen Idec Inc.

The undersigned, whose title is supplied below, is authorized to act on behalf of the assignee.

Respectfully submitted,



Christopher A. Dayton  
Associate General Counsel, IP  
Biogen Idec Inc.

8/22/05

Date